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INTRODUCTION
Epidermal growth factor (EGF), also referred to as epithe-
lial growth factor, is produced in various tissues and exerts 
stimulatory effects on cell growth, proliferation and survival. 
Because mutations of EGF receptor (EGFR) are observed in 
many human cancers, this receptor has been studied mainly as 
a target for anticancer therapy. Indeed, several EGFR inhibitors 
are currently available for the treatment of tumors. However, 
studies performed during the last decade strongly suggest that 
abnormal EGFR-mediated signaling plays an important role 
in cardiovascular pathology. EGFR is abundantly expressed 
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Epidermal growth factor receptor (EGFR) is a member of receptor tyrosine kinase family. Upon ligand binding, EGFR undergoes 
autophosphorylation at several tyrosine residues within its intracellular domain and triggers a number of signaling pathways 
including extracellular signal-regulated kinases, phospholipase Cγ, and phosphoinositide 3-kinase. EGFR regulates cell growth, 
proliferation and survival, and its overexpression or oncogenic mutations are observed in many human cancers. Therefore, several 
drugs have been developed to target EGFR for antitumor therapy. In the cardiovascular system, enhanced EGFR signaling is 
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rial hypertension. Stimulated EGFR induces vasoconstriction and regulates renal tubular Na+ transport. Apart from its cognate 
ligand, EGFR is activated by many vasoconstrictors including angiotensin II, norepinephrine and endothelin-1. Enhanced EGFR 
signaling has been observed in several animal models of hypertension, and synthetic EGFR inhibitors reduce blood pressure in 
some of these models. Leptin, a peptide hormone which is produced by white adipose tissue and circulates in increased amounts 
in obese subjects, transactivates EGFR in vascular wall and the kidney, and EGFR inhibitor, AG1478, reduces blood pressure 
in experimental hyperleptinemia, suggesting that leptin-induced activation of EGFR may be involved in the pathogenesis of 
hypertension associated with the metabolic syndrome. These data suggest that inhibiting EGFR could be a novel therapeutic 
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in the vascular wall and myocardium, and is activated not 
only by EGF itself but also by many vasoconstrictors such as 
angiotensin II, endothelin-1 and norepinephrine. Enhanced 
EGFR signaling has been demonstrated in experimental 
models of arterial hypertension and myocardial hypertrophy. 
Therefore, targeting EGFR is a promising therapeutic strategy 
for cardiovascular diseases. 
 The aim of this article is to provide general overview of 
EGFR signaling and to discuss role of this receptor in the 
regulation of vascular tone and renal sodium handling – two 
major determinants of blood pressure – under physiological 
conditions and in arterial hypertension. Moreover, potential 
therapeutic implications are also addressed. Role of EGFR 
in other aspects of cardiovascular pathology such as con-
genital heart defects, atherogenesis, myocardial hypertrophy, 
ischemia-reperfusion injury and hypertension-induced renal 
damage has been recently described in excellent reviews 
(1–3).
EGFR AND ITS LIGANDS: AN OVERVIEW
Family of ErbB receptors
EGF receptor was identified as a plasma membrane-bound
protein tyrosine kinase in 1980 (4). In 1984, Downward et al 
demonstrated that v-ErbB oncogene of avian erythroblastosis 
virus encodes a truncated form of EGFR (5). Currently, EGF 
receptor is classified as a first member of ErbB family of re-
ceptor tyrosine kinases, and thus is also referred to as ErbB1 
or HER1 (from Human Epidermal Growth Factor Receptor 
1). In 1984, Schechter et al identified neu oncogene in ethyl-
nitrosourea-induced neuroblastoma, and demonstrated its 
sequence similarity with v-ErbB (6); this oncogene encodes a 
cell surface protein having a molecular weight of 185 kD (7). 
The respective protein encoded by a cellular protooncogene 
was termed p185her2/neu (now referred to as HER2 or ErbB2); 
oncogenic protein differs from p185her2/neu by a single point 
mutation (valine to glutamic acid substitution at residue 664) 
(8). Two other members of ErbB family - ErbB3 and ErbB4 
- were identified later. Overexpression or oncogenic muta-
tions of ErbB receptors (in particular ErbB1 and ErbB2) are 
observed in many human tumors. Currently known members 
of the ErbB family and their ligands are listed in Table 1.
 All ErbB receptors are single-chain transmembrane proteins 
with its N-terminus outside and C-terminus inside the cell 
(Fig. 1). Upon ligand binding, the receptor dimerizes with the 
same (homodimerization) or other member of ErbB family 
(heterodimerization), and intracellular tyrosine kinase (TK) 
domain is activated to phosphorylate the receptor itself as well 
as various signaling proteins (see below). No ligand was identi-
fied for ErbB2, and recent studies indicate that conformation
of this receptor makes it unable to bind any ligand. Indeed, 
the conformation of extracellular domain of unliganded ErbB2 
resembles the conformation of ligand-bound form of other 
members. Therefore, ErbB2 is able to heterodimerize with 
other ErbB receptors, and is actually a preferred dimerization 
partner. When ErB2 forms dimer with other ErbB receptor, 
it may be phosphorylated by tyrosine kinase domain of its 
dimeric partner and vice versa, TK domain of ErbB2 may 
phosphorylate the intracellular domain of its partner. Conse-
quently, both components of the dimer are involved in signal 
transduction, although precise signaling pathways triggered 
by both partners are not necessarily identical (9).
 Apart from ErbB2, ErbB3 is also “atypical” in that it lacks 
the TK domain. Nevertheless, ligand-bound ErbB3 may non-
covalently activate its heterodimeric partner as well as may be 
Table 1. ErbB receptors and their ligands
Gene Receptor Ligands
c-ErbB (ErbB1) EGFR (ErbB1, HER1) EGF, TGF-α, HB-EGF, AR, EPR, BTC
neu p185her2/neu (ErbB2, HER2) -
ErbB3 ErbB3 NRG-1, NRG-2
ErbB4 ErbB4 NRG-1, NRG-2, NRG-3, NRG-4 HB-EGF, EPR, BTC
TGF-α – transforming growth factor-α, HB-EGF – heparin-binding epidermal growth factor, AR – amphiregulin,  
EPR – epiregulin, BTC – betacellulin, NRG - neuregulins
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phosphorylated by its partner to perform signal transduction. 
Despite “atypical” characteristics of its components, ErbB2/
ErbB3 heterodimer is a most potent mitogenic combination 
among all known ErbB dimmers.
 ErbB family is an evolutionary ancient signaling system 
which, however, was becoming more and more complicated 
during the evolution. For example, in Caenorhabditis elegans 
only one receptor homologous to mammalian ErbB is known 
(LET-23), and this receptor has only one ligand (LIN-3). In 
a fruitfly, Drosophila melanogaster, there is one ErbB-like 
receptor but it may be bound by 5 ligands. Interestingly, one of 
these ligands is a receptor antagonist, whereas no endogenous 
antagonists of ErbB receptors were found in mammals.
 ErbB receptors and their ligands are involved in the regu-
lation of cell growth, proliferation and survival. Although 
this signaling system plays an important role during the de-
velopment and in rapidly proliferating (e.g. epithelial) cells 
of the adult organism, it was studied mainly in the context 
of malignancies. Three types of abnormalities within this 
system may contribute to uncontrolled cell proliferation: (i) 
oncogenic mutations within the ErbB genes, which cause 
ligand-independent receptor overactivity, (ii) overexpression 
of ErbB receptors, and (iii) overexpression of their ligands. 
Abnormalities of the ErbB system have been observed in many 
cases of breast, gastric, ovarian, urinary bladder, pancreatic 
and other cancers (10).
EGF receptor: ligand binding and signaling 
mechanisms
Human EGFR consists of 1186 aminoacids (Fig. 1) and is 
a 170 kD protein originating from a 1210-residue precursor 
(9). Its extracellular domain consists of 4 subdomains which, 
counting from the N-terminus, are referred to as I, II, III and 
IV, or L1, CR1, L2 and CR2, respectively. Domains L1 and L2 
are involved in ligand binding. Upon interaction with ligand, 
conformation of the receptor changes such that domain CR1 
is exposed to bind CR1 domain of a dimeric partner. With the 
exception of ErbB2, other ErbB homo- and heterodimers are 
activated in a “2+2” manner, i.e. each of two receptors in its 
monomeric form binds one ligand, and then these two ligand-
bound monomers dimerize to form an active complex.
 Transmembrane domain of EGFR consists of 23 hydrophobic 
aminoacids. The role of juxtamembrane domain is unknown, 
however, it is suggested that this region is involved in sorting 
of newly formed receptors to the basolateral membranes of 
epithelial cells, as well as in internalization/downregulation 
of receptors upon ligand binding. The next tyrosine kinase 
domain (Fig. 1) phosphorylates the receptor itself (autophos-
phorylation) and intracellular signaling proteins. Finally, 
C-terminal domain contains 5 autophosphorylation tyrosine 
residues (Tyr992, Tyr1068, Tyr1086, Tyr1148 and Tyr1173), which 
bind various adaptor proteins containing Src homology-2 
(SH2) or phosphotyrosine-binding (PTB) domains (Table 2). 
Activated EGF receptor triggers many signaling pathways 
including (i) extracellular signal-regulated kinases (ERKs), 
(ii) phosphoinositide 3-kinase (PI3-K) – protein kinase B/Akt, 
and (iii) phospholipase Cγ.
 Extracellular signal-regulated kinases-1 and -2 (ERK1/2) 
are serine/threonine kinases belonging to a large family of 
mitogen-activated protein kinases (MAPKs), and due to their 
molecular weights are also referred to as p44 MAPK and p42 
MAPK, respectively. Most mitogenic and growth-promoting 
effects of EGFR are mediated by ERKs. ERKs are activated 
through the phosphorylation cascade including Ras protein, 
































Figure 1. Structure of human EGF receptor. Numbers of ami-
noacid residues forming the specific domains are presented
on the left (except the transmembrane domain), and tyrosine 
residues which are phosphorylated on the right. Length of 
consecutive domains is proportional to number of residues. 
TM, transmembrane domain, JM, juxtamembrane domain, TK, 
tyrosine kinase domain, CT, C-terminal domain.
4
Biomed Rev 18, 2007
 Bełtowski and Jamroz-Wiśniewska
kinases-1 and -2 (MAPKKs or MAP2Ks), also referred to 
as MAPK/ERK kinase-1 and -2 (MEK1 and MEK2), which 
finally phosphorylate ERK1 and ERK2, respectively (Fig. 2).
Phosphorylated EGFR recruits Growth hormone receptor-
binding-2 (Grb2) adaptor protein either directly or through 
Src homology-containing protein (Shc); in the latter case, 
Shc first binds to EGFR and then recruits Grb2. Under resting
conditions, Grb2 is constitutively bound to “Son of sevenless” 
(Sos) guanine nucleotide exchange factor. Relocation of Grb2-
Sos complex to the plasma membrane allows the interaction 
of Sos with membrane-bound Ras protein; consequently, Sos 
catalyzes the exchange of GDP for GTP thus converting Ras 
from its inactive to active form. GTP-bound Ras activates 
Raf kinase, which phosphorylates MEK1 and MEK2 (Fig.2). 
To become active, Ras proteins have to be farnesylated, e.g. 
bound to the farnesyl group (isoprenoid group produced from 
mevalonate) by protein farnesyltransferases. Ras possesses an 
intrinsic GTPase activity; this activity is enhanced by GAP 
(GTPase-activating proteins). Hydrolysis of Ras-bound GTP 
Table 2. Docking sites for signaling proteins within the 






Tyr1173 (for N-terminal SH2 domain of PLCγ)
Tyr992 (for C-terminal SH2 domain of PLCγ)





p85 of PI3-K Tyr920*
STAT-5 Tyr845*
Grb2 – growth hormone receptor-binding protein-2, 
Shc – Src homology-2 containing adaptor protein, PLCγ – 
phospholipase C-γ, p120 Ras GAP – GTPase activating protein 
of 120 kDa, PTP-1B – protein tyrosine phosphatase-1B, 
SHP-1 – Src homology-containing tyrosine phosphatase-
1, c-Src, c-Abl – nonreceptor tyrosine kinases, p85 of 
PI3-K – regulatory subunit of phosphoinositide 3-kinase, 
STAT-5 – signal transducer and activator of transcription-5. 

























Figure 2. Mechanisms of EGFR activation and transactiva-
tion, and activation of ERKs by EGFR. NOX, NADPH oxidase, 
MMP, matrix metalloprotease, P, phosphate group. Sites of 
action of selected inhibitors commonly used in experimental 
studies are indicated. PD98059 is frequently referred to as 
“ERK inhibitor”, although in fact it inhibits ERK phospho-
rylation by MEKs, so could be rather referred to as “MEK 
inhibitor”.
to GDP inactivates Ras and terminates Raf-MEK-ERK signal-
ing.
 The second pathway triggered by EGFR is PI3-K. PI3-K 
phosphorylates phosphoinositides at 3-position of inositol 
ring thus converting phosphatidylinositol 4,5-bisphosphate 
to phosphatidylinositol 3,4,5-triphosphate, or phosphatidyli-
nositol 4-phosphate to phosphatidylinositol 3,4-bisphosphate. 
These phosphoinositides activate phosphoinositide-dependent 
protein kinases-1 and -2 (PDK-1 and PDK-2), which then 
phosphorylate and activate protein kinase B (Akt). PI3-K-
PKB/Akt pathway inhibits apoptosis and plays an important 
role in the regulation of cell survival. One of the PKB sub-
strates is mammalian target of rapamycin (mTOR), which 
activates ribosomal p70S6 kinase and thus stimulates protein 
synthesis. EGFR also activates several phospholipases and 
enhances breakdown of membrane phospholipids. Phospholi-
pase Cγ (PLCγ) is phosphorylated by TK domain of EGFR and 
hydrolyzes membrane phosphatidylinositol 4,5-bisphosphate 
to diacylglycerol (DAG), which activates protein kinase C 
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(PKC), and inositol 1,4,5-triphosphate (IP3), which releases 
Ca2+ from intracellular stores. Phospholipase D, which is also 
activated by EGFR in some experimental systems, hydrolyzes 
phosphatidylcholine to choline and phosphatidic acid; the latter 
is an important second messenger. Finally, EGFR may activate 
phospholipase A2 which releases arachidonic acid, however, 
this effect is indirect and results from the stimulation of other 
signaling pathways. EGFR may also recruit and phosphorylate 
Signal Transducer and Activator of Transcription-5 (STAT-5) 
protein, which then translocates to cell nucleus and regulates 
gene expression. In addition, EGFR may phosphorylate non-
receptor tyrosine kinases such as Janus kinase-2 (JAK-2) or 
c-Src kinase. Finally, EGFR activates protein tyrosine phos-
phatase SHP-1, which dephosphorylates the receptor itself as 
well as its substrates thus terminating signaling process. All 
these pathways are connected by multiple relationships thus 
forming a very complex signaling network. EGFR-mediated 
signaling is facilitated by reactive oxygen species. Indeed, 
EGF stimulates formation of hydrogen peroxide (H2O2), which 
transiently inactivates protein tyrosine phosphatases and thus 
blocks their inactivating effect on EGFR (11).
ErbB receptor ligands
All ErbB receptor ligands are synthesized as plasma mem-
brane-bound precursors from which mature soluble growth 
factors are released. Interestingly, both soluble and membrane-
bound ligands can bind to their receptors. Membrane-bound 
ligands bind only receptors on adjacent cells (juxtacrine 
signaling), whereas soluble ligands signal in a paracrine/au-
tocrine manner. All ligands contain a characteristic EGF-like 
domain consisting of 40-50 aminoacids. This domain contains 
6 spatially conserved cysteine residues arranged in a sequence 
CX7CX4-5CX10-13CXCX8C (C-cysteine, X-any aminoacid), 
and linked by three disulfide bonds in a pattern C1-C3, C2-C4
and C5-C6. Ligands of ErbB receptors may be classified into
three groups (Table 1): (i) epidermal growth factor (EGF), 
transforming growth factor-alpha (TGF-α) and amphiregulin 
(AR), which bind only EGFR, (ii) heparin-binding epidermal 
growth factor (HB-EGF), epiregulin (EPR) and betacellulin 
(BTC), which bind EGFR and ErbB4, and (iii) neuregulins 
(NRG), which bind either ErbB3 and ErbB4 (NRG-1, NRG-2) 
or only ErbB4 (NRG-3 and NRG-4).
 EGF is an archetypical growth factor which was first iso-
lated from mice submandibular gland and identified because
of its effect on tooth eruption and eyelid opening in newborn 
animals (12). Its human equivalent was initially called β-uro-
gastrone, because was isolated from urine and demonstrated 
to inhibit gastric acid secretion (13). In humans, prepro-EGF 
gene consists of 24 exons and encodes a 1207-residue precur-
sor containing 9 EGF-like domains in its extracellular portion. 
The domain closest to the plasma membrane is released as a 
mature 53-aminoacid EGF, whereas the fate of additional 8 
domains is unknown. EGF is detected in blood at a picomolar 
range, most of it being associated with platelets.
 The second EGFR ligand, TGF-α, was isolated from culture 
media of retrovirally transformed fibroblasts as a “sarcoma
growth factor” (14), but is also synthesized in normal tissues 
such as decidua, brain, keratinocytes, kidneys and macro-
phages. HB-EGF was identified in conditioned medium of
human macrophages as a mitogenic growth factor with high 
affinity to heparin. A characteristic feature of mature HB-EGF
is its heparin-binding domain localized N-terminally to the 
EGF-like domain. Interaction of this domain with cell surface 
heparan sulfate facilitates binding of HB-EGF with its recep-
tors. Apart from being a precursor of mature growth factor, 
membrane-bound proHB-EGF is a receptor for diphtheria 
toxin (DT) and mediates its entry to the cells. DT binds to 
aminoacids 106-149 within the EGF-like domain, and there-
fore cannot bind to truncated HB-EGF which remains in the 
membrane after cleavage of soluble growth factor. CRM197 is 
a nontoxic DT analogue with a point mutation in the catalytic 
domain. CRM197 binds to both membrane-bound and solu-
ble HB-EGF and blocks its interaction with target receptors. 
Therefore, CRM197 is used in experimental studies to block 
both paracrine/autocrine and juxtacrine HB-EGF signaling. 
CRM197 is specific for HB-EGF and does not bind to other
ErbB ligands. HB-EGF is widely expressed in various tis-
sues including vascular endothelial and smooth muscle cells 
(15–17).
 Other ligands of ErbB receptors have more restricted tissue 
distribution and their role is less recognized. Amphiregulin 
(AR) was identified as an EGFR ligand produced by breast
adenocarcinoma cell line; its name derives from the observa-
tions that AR may either stimulate or inhibit cell proliferation 
(reviewed in 18). Betacellulin (BTC) was isolated from culture 
media of pancreatic β-cell tumor line, however, is expressed 
also in normal tissues including pancreas, liver, kidney, small 
intestine, vascular smooth muscle and endothelial cells (for 
review, see ref. 19). Epiregulin (EPR) was purified from con-
ditioned media of the mouse fibroblast-derived tumor cell line,
but is also synthesized by vascular smooth muscle cells (20). 
Neuregulins (NRG) or heregulins (HRG) create a family of 
four peptides encoded by separate genes with diverse tissue 
distribution and regulatory roles (reviewed in 21, 22).
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 Soluble ErbB receptor ligands are cleaved from their mem-
brane-bound precursors by either soluble matrix metallopro-
teases (MMPs) or membrane-bound metalloproteases belong-
ing to “A Disintegrin And Metalloprotease” (ADAM) family. 
The identity of cleaving enzymes was identified established 
only in some experimental systems and, probably, each ligand 
precursor may be cleaved by more than one protease depending 
on the cell type and stimulus. However, it is generally appreci-
ated that ADAMs are most important sheddases. ADAMs are 
transmembrane proteins consisting of (i) N-terminal signal 
sequence, (ii) prodomain, (iii) metalloprotease (MP) domain, 
(iv) disintegrin domain, (v) cysteine-rich region, (vi) EGF-like 
domain, (vii) transmembrane domain,  and (viii) cytoplasmic 
domain. The first recognizedADAMs (ADAM1 andADAM2)
were two subunits of a heterodimeric sperm protein, fertillin. 
Subsequently identified ADAMs are being numbered in an or-
der in which they are discovered. Currently (December 2007), 
40 ADAMs are known (the complete list is available online 
at http://people.virginia.edu/~jw7g/Table_of_the_ADAMs.
html). However, only half of ADAMs bear the MP catalytic 
consensus motif, and catalytic activity was confirmed only for
some of them. Gene knockout experiments revealed that tumor 
necrosis factor-α converting enzyme (TACE or ADAM17) 
plays an important role in the cleavage of ErbB receptor lig-
and precursors; other enzymes implicated in this process are 
ADAM9, ADAM10 and ADAM12 (23).
TRANSACTIVATION OF EGFR BY VASOACTIVE MEDIATORS
In 1996 Daub et al (24) observed that several agonists of 
G-protein coupled receptors (GPCR) such as endothelin-1, 
lysophosphatidic acid and thrombin, rapidly activated EGFR 
and ErbB2 in Rat-1 fibroblasts. The phenomenon was too rapid
to be mediated by stimulation of ligand synthesis de novo, and 
therefore was named “transactivation”, i.e. ligand-independ-
ent activation. The term “transactivation” is now commonly 
used to describe activation of EGFR by factors other than 
peptide ligands listed in Table 1, although it is evident that in 
most cases this phenomenon is in fact ligand-mediated. The 
most common mechanism of EGFR transactivation was first
characterized in 1999, when Prenzel et al (25) observed that 
many GPCR ligands activate EGFR by stimulating HB-EGF 
cleavage from its membrane precursor; the mechanism referred 
to as “triple membrane spanning signaling” (Fig. 2).
 Several other mechanisms of EGFR transactivation have 
been described. Non-receptor tyrosine kinase, c-Src, phospho-
rylates EGFR at Tyr845 within its TK domain and stimulates 
receptor kinase activity (26). Moreover, growth hormone and 
prolactin activate EGFR by inducing its phosphorylation at 
Tyr1068 by JAK2. Because this residue is a Grb2-docking site, 
JAK2 may trigger downstream ERK signaling even by mutant 
EGFR devoid of its TK activity (27). A nonreceptor Ca2+-de-
pendent tyrosine kinase, proline-rich tyrosine kinase (Pyk2) 
belonging to the focal adhesion kinase (FAK) family, has also 
been implicated in EGFR activation. Reactive oxygen species 
(ROS) may activate EGFR through multiple mechanisms. 
First, ROS inactivate protein tyrosine phosphatases and thus 
enhance EGFR activity by inhibiting its dephosphorylation. 
Second, ROS activate intermediate kinases which subsequently 
phosphorylate EGFR, such as c-Src or JAK-2. Third, ROS 
activate ADAMs and MMPs and stimulate ligand shedding 
(28). The relationship between various EGFR-transactivation 
pathways is complex and cell-specific. In addition, many of
these pathways such as c-Src, JAK2 and ROS may also be 
activated by EGFR.
 The interest in role of EGFR in cardiovascular system has 
emerged when it was realized that this receptor is transacti-
vated in the vascular wall and myocardium by vasoactive me-
diators such as angiotensin II, endothelin-1 or catecholamines 
– which not only induce vasoconstriction but also stimulate 
vascular and myocardial hypertrophy. Below are briefly char-
acterized mechanisms of EGFR transactivation by mediators 
most relevant for cardiovascular (patho)physiology.
Angiotensin II
Angiotensin II (AII) – the major executor of the renin-angi-
otensin-aldosterone system – is one of the principal mediators 
regulating vascular tone and vascular smooth muscle cell 
hypertrophy and proliferation. Most effects of AII are mediated 
by AT1 receptor, a serpentine receptor coupled to Gq protein 
which stimulates phospholipase C to produce DAG and IP3 
from membrane phosphoinositides. DAG/PKC and IP3/Ca2+ 
pathways mediate fast contraction of vascular smooth muscle 
cells in response to angiotensin II. However, AII also activates 
many other signaling pathways including ERKs, which play an 
important role in hypertrophic effect of the peptide. Currently 
available evidence suggest that EGFR is a central link between 
AT1 receptors and many protein kinases such as ERK, c-jun 
N-terminal kinase (JNK), p38 MAPK, c-Src, etc.
 Various mechanisms of EGFR activation by angiotensin II 
have been described in the cardiovascular system depending 
on cell type and experimental conditions (Table 3). It should 
be noted that most studies were performed on isolated or 
cultured cells. Thus, the relevance of these findings to a com-
plex structure of vascular wall is not clear. Moreover, some 
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Table 3. Transactivation of EGFR in the vascular wall by angiotensin II.
Cells Signaling pathway leading to EGFR activation
Increase in EGFR 
phosphorylation
EGFR inhibitor-sensitive 
biological outcome Ref. 
In vitro studies
Rat cardiac fibroblasts Ca2+-CM + ERK activation, DNA synthesisIncreased expression of c-fos (29)
Rat ventricular myocytes AT1-PKC ?
ERK activation, stimulation of 
sarcolemmal NHE1 (30)
Neonatal rat cardiomyocytes ADAM12/HB-EGF + Cell hypertrophy (31)
Rat aortic SMC AT1-Ca2+-Src +
ERK activation,  
protein synthesis (32, 33)
Rat aortic SMC AT1-Gq-IP3-Ca2+-Pyk2-Src ?
Activation of ERK and PI3-K DNA 
synthesis (34, 35)
Rat aortic SMC AT1-Ca
2+-MMP/ADAM-HB-
EGF +
Activation of ERK  
and p38 MAPK (36)
Rat aortic SMC ROS-c-Src + (Y1068, Y1173) ? (37)
Rat aortic SMC PKC-NOX-ROS-Src ? PI3-K-NOX-ROS (38)
Rat aortic SMC AT1-Ca2+-H2O2-ADAM + (Y1068)
ERK activation, protein synthesis, 
cell growth and migration (39)
Rat aortic SMC ? + (Y845) Activation of PKB/Akt and p70S6K, protein synthesis (40)
Rat aortic SMC Ca2+-Ca/CMKII-Pyk2/Src + ERK stimulation (41)
Rat aortic SMC AT1-ADAM17-HB-EGF + (Y1068) Protein synthesis , cell hypertrophy (42)
Rat mesenteric artery SMC AT1-? ? NOX-ROS-ERK/p38 MAPK (43)
Rat aortic SMC MMP/HB-EGF + (Y1173) Activation of ERK and PKB/Akt Cell migration and proliferation (44)
Rat aortic SMC cPLA2-AA metabolites-p38MAPK-PLD2-PA
+ (Y1068) Activation of PKB/Akt (45)
Human coronary artery SMC
Gq protein-independent 
direct interaction between 
AT1 and EGFR
? ERK stimulation, cell proliferation (46)




ERK activation, induction of Angpt2 
and VEGF, angiogenesis (47)
Human umbilical vein EC ? ? Phosphorylation of FAK and paxillin (a FAK substrate), cell migration (48)




+ (acute)  
– (3-day) ? (50)
Rat aorta 
(AII infusion for 26h) ? + (Y
845) Protein synthesis (40)
Mice aorta  
(AII infusion for 24h) AT1-ROS-Src-cAbl-caveolin-1 + ? (51)
Rat mesenteric artery (AII 
infusion for 26h) ? ? Protein synthesis (52)
CM – calmodulin, PKC – protein kinase C, NHE – sodium/proton exchanger, NOX – NADPH oxidase, CMKII – calmodulin-
dependent protein kinase II, p70 S6K – ribosomal p70 S6 kinase, cPLA2 – cytosolic phospholipase A2, PLD2 – phospholipase D2, 
PA – phosphatidic acid, Angpt2 – angiopoietin 2, VEGF – vascular endothelial growth factor, FAK – focal adhesion kinase.
“+” – increase in EGFR phosphorylation upon AII treatment was demonstrated, if specific Tyr residues which are phosphorylated
were identified, they are presented in parentheses, “?” – EGFR phosphorylation was not examined, and conclusion about
receptor activation is based solely on the sensitivity of response to EGFR inhibitors
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links in the signaling cascade have sometimes been omitted 
in the study design, and alternative possible mechanisms 
have not always been tested. Therefore, the specific signaling
mechanisms deciphered in various studies do not necessarily 
exclude one another. Nevertheless, some general conclusions 
may be drawn by analyzing the results. There is little doubt 
that AII transactivates EGFR through the AT1 receptor. In 
addition, c-Src-mediated EGFR phosphorylation or metal-
loprotease-dependent HB-EGF shedding seem to be the two 
major mechanisms of receptor transactivation, although c-Src 
activation may be Ca2+-dependent (33), ROS-dependent (37) 
or may involve Ca2+-sensitive nonreceptor tyrosine kinase, 
Pyk2 (34). The identity of MMP/ADAMs involved in HB-EGF 
shedding has been established definitely only in one study
(42). It should be noted that although sensitivity of biological 
outcome to EGFR inhibitors (usually AG1478) was demon-
strated in many cases, phosphorylation of this receptor was 
directly examined only in some studies and if was examined, 
the identity of Tyr residue(s) which are phosphorylated has 
not always been established. 
 Seshiah et al (38) described the interesting feed-forward 
mechanism of the prooxidant effect of AII in smooth muscle 
cells. It was demonstrated that AII induces a biphasic ROS 
formation. The early phase (minutes) results from PKC-medi-
ated stimulation of vascular NADPH oxidase (NOX). Then, 
NOX-derived ROS stimulate c-Src, which phosphorylates 
EGFR leading to downstream activation of PI3-K. The late 
phase (hours) of AII-induced ROS formation results from 
EGFR and PI3-K-mediated NOX activation (38). Thus, ROS 
may operate both upstream and downstream from EGFR.
 Seta et al (53) have demonstrated that in COS-7 cells 
transfected with AT1 and EGF receptors, AII transactivates 
EGFR by stimulating AT1 phosphorylation at Tyr319 within 
its C terminus. Phosphorylated AT1 activates EGFR by direct 
interaction between these receptors, independently of any G 
protein. Substitution of Tyr319 by glutamic acid, which mimics 
phosphorylation by incorporating negatively charged residue, 
results in constitutive activation of EGFR, although this muta-
tion has no effect on AT1-Gq-PLC signaling. Miura et al. have 
demonstrated that G protein-independent mechanism operates 
also in native human coronary artery smooth muscle cells (46). 
Interestingly, AII analogue with Tyr4 and Phe8 substituted by 
isoleucines selectively activates this AT1-EGFR-ERK pathway 
but fails to stimulate Gq protein-PLC signaling (54). On the 
contrary, AT1 Tyr319Phe mutant, which cannot be phosphor-
ylated, is unable to interact with and activate EGFR, but nor-
mally stimulates Gq protein. Transgenic mice expressing this 
mutant fail to develop cardiac hypertrophy and do not exhibit 
increase in EGFR phosphorylation in response to angiotensin 
II (55).
 High concentration of glucose (27.5 mM) augments AII-in-
duced EGFR transactivation in vascular smooth muscle cells. 
In contrast, glucose has no effect on EGF-induced EGFR phos-
phorylation. This effect of glucose is associated with enhanced 
N-glycosylation of EGFR. It has been demonstrated that 
145 kD form of EGFR (predominant under normoglycemic 
conditions) can be activated by EGF but not transactivated 
by AII, whereas heavily glycosylated 170 kD EGFR is ef-
ficiently stimulated by various agonists of G-protein coupled
receptors such as AII, thrombin and sphingosine 1-phosphate 
(56). These data indicate that diabetes mellitus may augment 
transactivation of EGFR by AII, and this mechanism probably 
contributes to abnormalities of vascular tone (see below) and 
enhanced smooth muscle cell hypertrophy/proliferation in 
hyperglycemic states.
 Although most effects of angiotensin II are mediated by AT1 
receptors, stimulation of less abundant AT2 receptors opposes 
some of them. Indeed, AT2 receptors inhibit vascular smooth 
muscle cell growth/proliferation and induce vasodilation (57). 
Stimulation of AT2R opposes AT1R-induced EGFR phospho-
rylation in vascular smooth muscle cells, and this effect is 
mediated by stimulation of tyrosine phosphatase SHP-1 which 
dephosphorylates EGFR (47,58).
 Stimulation of AT1 receptors results in their movement to 
caveolae, which are microdomains of plasma membrane rich 
in cholesterol and sphingolipids and also contain caveolin-1. 
A significant fraction of unstimulated EGFR is localized in
caveolae under resting conditions (59). Within caveolae, AT1 
interacts with EGFR leading to their phosphorylation by c-Src 
which is also concentrated therein. In addition, c-Src phos-
phorylates caveolin-1 thus decreasing its affinity to EGFR.
Consequently, AII induces rapid movement of phosphorylated 
EGFR out of caveolae and its concentration in focal adhesions, 
where it interacts with vinculin and paxillin. Both depletion of 
membrane cholesterol (which disrupts caveolae) and disrup-
tion of focal adhesions by actin-depolymerizing agents such 
as cytochalazin D, inhibit AII-induced EGFR transactivation 
in vascular smooth muscle cells (59). Thus, caveolae and fo-
cal adhesions are specialized membrane microdomains which 
play an important role in AII-induced EGFR transactivation. 
It is postulated that binding of angiotensin II to AT1 receptors 
triggers the following sequence of events (i) movement of 
AT1 to caveolae, (ii) ROS formation and stimulation of c-Src, 
(iii) phosphorylation of EGFR and caveolin-1 by c-Src, and 
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(iv) movement of phosphorylated EGFR out of caveolae and 
their concentration in focal adhesions (60). This “localized” 
signaling allows stimulating EGFR-mediated response with-
out widespread activation of AT1-stimulated pathways such 
as ROS and c-Src in the whole cell. Moreover, nonreceptor 
tyrosine kinase c-Abl may be an intermediate between c-Src 
and phosphorylation of caveolin. Inhibition of c-Abl impairs 
angiotensin II-induced traffic of AT1 to caveolae and subse-
quent activation of EGFR both in vitro and in vivo (51).
Catecholamines
Two studies reported transactivation of EGFR by catecho-
lamines in the vascular wall. Phenylephrine stimulates EGFR 
phosphorylation, ERK activity, and protein synthesis in 
isolated balloon-injured rat thoracic aorta (61). This effect is 
abolished by AG1478, CRM197, anti-HB-EGF neutralizing 
antibody, MMP inhibitors and HB-EGF gene knockout, sug-
gesting that phenylephrine stimulates MMP-dependent proHB-
EGF shedding. In addition, Hao et al. (62) have demonstrated 
that phenylephrine stimulates EGFR phosphorylation at Tyr1173 
in rat mesenteric arteries in AG1478-sensitive manner.
Endothelin-1
Endothelin-1 (ET-1) is a potent vasoconstrictor, growth factor 
and vascular cell mitogen. In smooth muscle cells isolated 
from rat thoracic aorta, ET-1-induced DNA synthesis was 
dose-dependently inhibited by AG1478 (63). ET-1 stimu-
lated EGFR phosphorylation, its association with Grb2, and 
ERK phosphorylation in these cells, which was abolished by 
AG1478 (64). The precise mechanism of ET-1-induced EGFR 
activation was not established, however, it was demonstrated 
that ETA receptor and increase in intracellular Ca2+ were in-
volved (64). In contrast, in neonatal rat cardiomyocytes, ET-1 
transactivates EGFR in MMP and PKC-dependent but Ca2+, 
Pyk2 and Src-independent manner (65). In smooth muscle 
cells isolated from rabbit internal carotid artery, ET-1-induced 
EGFR phosphorylation was sensitive to deficiency of extra-
cellular Ca2+ but not to nifedipine, indicating that Ca2+ influx
from extracellular space by voltage-independent (nifedipine-
insensitive) Ca2+ channels mediated this effect (66). Flamant 
et al (67) have shown that ET-1 increases EGFR and ERK 
phosphorylation level in isolated mice aorta and that these 
effects are abolished by EGFR inhibitor, PD153035, as well as 
by endothelin receptor antagonist, bosentan. In smooth muscle 
cells isolated from rabbit carotid artery, ET-1 increased ERK 
phosphorylation in AG1478-sensitive manner, suggesting the 
involvement of EGFR (68).
Aldosterone
Recent studies indicate that aldosterone does not only regulate 
renal Na+ handling, but has also many direct effects in the 
cardiovascular system, including stimulation of ROS forma-
tion and inducing myocardial fibrosis (69). Some of injurious
effects of aldosterone are mediated by EGFR. Aldosterone 
exerts two effects on EGFR (i) increases receptor density by 
stimulating its gene expression in mineralocorticoid receptor 
(MR)-dependent manner, and  (ii) transactivates EGFR by 
rapid non-genomic mechanism (70).
 Stimulation of EGFR expression by aldosterone was first
described in Chinese hamster ovary cells (71). Recently, Gross-
man et al (72) have demonstrated that aldosterone infused by 
osmotic minipumps increases EGFR expression in aorta and 
myocardium of adrenalectomized rats, but has no effect on 
receptor level in adipose tissue and liver. The similar effect 
of aldosterone was observed in vitro in human aortic smooth 
muscle cells.
 Mazak et al (73) have demonstrated that aldosterone rap-
idly augments angiotensin II-induced EGFR transactivation 
in rat aortic smooth muscle cells, and this effect is abolished 
by spironolactone, superoxide scavenger, tiron, and reduced 
glutathione. Similarly, aldosterone augmented mitogenic ef-
fect of angiotensin II on rat aortic SMCs by increasing EGFR 
phosphorylation level (74).  In rat aortic endothelial cells, 
aldosterone increases angiotensin converting enzyme (ACE) 
expression, the effect partially attenuated by AG1478 (75). 
The mechanism through which aldosterone transactivates EGF 
receptor is unclear, but may include ROS, c-Src and MMP-
dependent shedding of EGFR ligand(s). 
EGFR AND VASCULAR TONE
Many signaling pathways triggered by EGF receptor, such as 
IP3-induced increase in intracellular Ca2+ and PKC are well-
known stimulators of vascular smooth muscle cell contrac-
tion. Moreover, ERK and PI3-K have also been implicated in 
vasoconstrictor response. However, the effect of EGF itself 
on vascular tone is controversial.
 Sumi et al (76) demonstrated that intravenously administered 
human EGF reduced blood pressure by about 8% in anesthe-
tized dog. Consistently with this, EGF infused intraarterially 
potently relaxed femoral, mesenteric, coronary, carotid and 
renal vascular beds in this species (77). Similarly, in conscious 
monkeys BP was decreased by 14-27% following EGF infu-
sion (78). In contrast, human EGF fragment (aminoacids 1-48) 
infused intravenously tended to increase BP in conscious rat 
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(although the effect did not reach the level of significance)
(78). On the other hand, Gan et al (79) observed no effect of 
EGF administered at a very high dose (30 mg/kg) on regional 
hemodynamics in anesthetized rat. Taken together, the results 
of in vivo studies are inconsistent and suggest that EGF has a 
weak and possibly species- and vascular bed-specific effect
on vascular tone.
 In vitro, EGF constricted rat aortic rings at nanomolar 
concentrations with maximal constriction approaching 40% 
of the effect of angiotensin II (80). Moreover, EGF aug-
mented vasoconstrictor effect of angiotensin II on isolated 
rat pulmonary artery (81). Similarly, EGF itself constricted 
rabbit aortic rings (82) and augmented constricting effect of 
bradykinin B1 receptor agonist (83). In contrast, Namiki and 
Akatsuka (84) observed that EGF dilated isolated rat aortic 
rings preconstricted with prostaglandin F2 or norepinephrine. 
This effect was endothelium-dependent and was abolished by 
soluble guanylate cyclase inhibitor, suggesting the involve-
ment of endothelium-derived nitric oxide. Similarly, EGF 
impaired constrictor response of dog coronary artery strips to 
norepinephrine, although had no effect on vascular tone per 
se (77).
 These inconsistent results do not exclude an important 
role of EGFR signaling in the regulation of vascular tone for 
several reasons. First, exogenous EGF or other EGFR ligands 
are rapidly metabolized and may have limited access to their 
receptors. Second, EGF may have various effects on differ-
ent vascular beds resulting in little or no net hemodynamic 
changes. Finally, EGFR “transactivated” by vasoactive media-
tors may play a more important role than stimulation of this 
receptor by its cognate ligands.
 Despite many studies reporting transactivation of EGFR by 
vasoactive mediators (see above), only few of them addressed 
the role of this receptor in the regulation of vascular tone. 
Hao et al (62) have demonstrated that phenylephrine induces 
sharp and long-lasting contraction of isolated rat mesenteric 
artery, and that two structurally unrelated EGFR inhibitors, 
AG1478 and PD153035, abolished the late phase of phenyle-
phrine-induced vasoconstriction. In contrast, these inhibitors 
had no effect on either basal vascular tone or on KCl-induced 
vasoconstriction. The effect of EGFR inhibitors was mimicked 
by ERK but not by p38 MAPK or PI3-K inhibitors, suggesting 
the major role of ERK in vasoconstriction. In addition, vaso-
constriction induced by α1-adrenergic agonists was abolished 
by CRM197 and anti HB-EGF antibody, as well as by MMP 
inhibitor, GM6001 (62). Subsequently, the same group has 
demonstrated that EGFR transactivated by phenylephrine 
increases ROS formation specifically in mitochondria, which
is accompanied by hyperpolarization of internal mitochondrial 
membrane, suggesting enhanced mitochondrial oxidation. 
Combined pharmacological and genetic approaches have re-
vealed that inhibiting mitochondrial ROS formation attenuates 
vascular effect of phenylephrine (85). The mechanism through 
which EGFR stimulates mitochondrial ROS formation, and 
how mitochondrial ROS increase vascular tone, remains to 
be established. Flamant et al (67) have demonstrated that 
ET-1-induced contraction of mice aortic rings is abolished 
by EGFR inhibitor, PD153035. In addition, increase in blood 
pressure induced by bolus intravenous ET-1 in anesthetized 
mice is reduced by pretreatment with either PD153035 or 
AG1478, whereas neither of these inhibitors has any effect 
on BP in animals not receiving ET-1 (67). Moreover, ET-1-
induced increase in blood pressure is markedly impaired in 
waved-2 mice, which bear spontaneous mutation in the egfr 
gene. Similarly, BP-elevating effect of ET-1 is attenuated in 
HB-EGF-/- mice (86). In vitro, ET-1 induced contraction of 
isolated carotid artery segments is attenuated in waved-2 mice 
and in HB-EGF-/- mice, whereas these genotypes have no effect 
on KCl-induced contraction (86). It has been demonstrated 
that these mutations, as well as pharmacological blockade of 
EGFR, PI3-K, HB-EGF or MMP in wild-type mice reduced 
ET-1-induced Ca2+ influx to mice and human vascular smooth
muscle cells (86). Moreover, AG1478 inhibited ET-1-induced 
EGFR phosphorylation and contraction of rabbit basilar artery 
rings in a dose-dependent manner both in vitro and in vivo 
(87).
 Carmines et al (88) have demonstrated that AII-induced 
constriction of isolated rat renal afferent and efferent arterioles 
was abolished by AG1478 but not by EGFR-inactive analogue, 
AG9. In contrast, Escano et al have recently demonstrated that 
AII stimulates ERK in SMCs isolated from rat renal microves-
sels in EGFR-independent but Src-dependent manner, whereas 
stimulation of ERK in SMCs isolated from thoracic aorta is 
EGFR-dependent (89). These data suggest that EGFR is in-
volved in vascular effect of angiotensin II only in large conduit 
vessels which are not involved in the regulation of peripheral 
resistance and blood pressure. Consistently with this, AG1478 
had no acute effect on blood pressure either in control or in 
angiotensin II-infused rats (40,89). Finally, Lucchesi et al. 
(90) have demonstrated that MMP2 and/or MMP9-mediated 
HB-EGF shedding and EGFR transactivation contribute to 
the development of myogenic tone (vasoconstriction induced 
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by increased perfusion pressure) in mouse mesenteric artery. 
Taken together, these data suggest that EGFR mediates vaso-
constriction in response to various humoral and mechanical 
factors, at least in some vascular beds.
EGFR AND RENAL SODIUM HANDLING
EGF is synthesized in the medullary thick ascending limb of 
the loop of Henle (mTAL) and in distal convoluted tubule 
(DCT) of various mammalian species (91,92). ProEGF is 
detected in the apical membrane of tubular cells, and mature 
EGF is cleaved to the tubular fluid and is excreted in urine at
relatively high levels (10-7-10-8 M versus 10-11M in plasma). 
Removal of salivary glands, a major source of plasma EGF 
(12), has no effect on EGF excretion in urine, suggesting that 
the kidney is a predominant source of urinary peptide (93). 
Interestingly, EGF receptors are localized in the basolateral 
membranes of tubular cells making it unlikely that locally 
generated EGF binds to these receptors. However, other EGFR 
ligands such as TGFα and HB-EGF are also abundantly ex-
pressed in the kidney. TGFα is synthesized in medullary and, 
to a lesser extent, in cortical collecting ducts (94). The high-
est density of EGF receptors is detected in proximal straight 
tubule (PST), followed by proximal convoluted tubule (PCT), 
cortical collecting duct (CCD), inner medullary collecting duct 
(IMCD), outer medullary collecting duct (OMCD) and distal 
convoluted tubule (95). It should be noted that EGF receptors 
are expressed only at low level in DCT and are not expressed at 
all in mTAL, two major sites of intrarenal EGF production.
 EGF is a potent mitogen for renal tubular and mesangial 
cells and, therefore, renal EGFR signaling has been studied 
mainly in the context of hyperproliferative kidney diseases 
such as diabetic nephropathy. EGFR plays an important role 
in renal regeneration after acute toxic or ischemic insults. In 
addition, abnormal EGFR sorting to the apical membranes of 
tubular cells may contribute to the development of polycystic 
kidney diseases. Much less is known about the role of EGF 
and its receptor in the regulation of renal sodium handling. 
The results of in vivo studies examining the effect of EGF 
on renal function are controversial. Infusion of EGF to the 
renal artery of anesthetized rat induces reversible decrease in 
glomerular filtration rate (GFR) due to constriction of pre- and
postglomerular vessels (reduced renal blood flow), and me-
sangial cell contraction (decrease in filtration fraction). These
effects result in the decrease in sodium and potassium excre-
tion, however, urine volume does not change, which suggests 
increased free water clearance (96). In contrast, infusion of 
betacellulin by osmotic minipumps for 7 days increased urine 
output by almost 100% in the rat (97). Intravenously infused 
EGF increased urine output and Na+ excretion but had no ef-
fect on K+ excretion in conscious sheep, suggesting that renal 
effect of EGF may be species-dependent (98,99). These vari-
able results may result, at least in part, from opposite effects 
of EGF on transport in various tubular segments and on other 
processes affecting renal Na+ handling, such as renal vascular 
tone or renin secretion. Indeed, EGF and TGF-α reduce renin 
secretion by rat renal cortical slices (100).
 If effect of EGF on tubular sodium transport is considered, 
both stimulation and inhibition have been observed depending 
on species, tubule segment and experimental conditions. Thus, 
EGF inhibited Na+ reabsorption by isolated rabbit CCD by 
44-59% (101), most likely by inhibiting amiloride-sensitive 
epithelial sodium channels (ENaC) (102). Incubation of im-
mortalized murine collecting duct cell line, mCT1, with EGF 
or TGF-α for 24 hours resulted in ERK-dependent inhibition 
of amiloride-sensitive Na+ current and reduction of mRNAENaC 
level, suggesting long-term regulation of ENaC by EGF 
(103). Interestingly, aldosterone increases EGFR expression 
in Madin-Darby Canine Kidney (MDCK) cells, which results 
in AG1478-sensitive and ERK-dependent inhibition of ENaC 
(104). It is suggested that stimulation of EGFR by aldosterone 
is a negative feedback mechanism aimed to limit the stimu-
latory effect of this mineralocorticoid on sodium transport. 
Moreover, AG1478 and U0126 which inhibit EGFR and ERK, 
respectively, reduce basal Na+ transport in MDCK cells, sug-
gesting that EGFR-dependent inhibition of ENaC operates 
even without stimulation with exogenous EGF or aldosterone, 
possibly due to autocrine signaling of membrane-bound EGFR 
agonist(s) (104). Tong and Stockand have demonstrated that 
EGF reduces ENaC open probability without affecting the 
number of channels in the plasma membrane (105). This ef-
fect of EGF results from PLCγ-mediated depletion of plasma 
membrane phosphatidylinositol 4,5-bisphosphate, an allosteric 
activator of ENaC, but is not associated with channel phos-
phorylation.
 However, stimulatory effect of EGF on Na+ transport has 
also been observed. EGF stimulates Na+-dependent phosphate 
reabsorption in in vitro microperfused rabbit proximal tubule 
(106) and in cultured porcine PCT-derived LLC-PK1 cells 
(107). Moreover, EGF stimulated HCO3-- dependent Na+ up-
take by rabbit proximal tubular cells (108). Gekle et al. (109) 
have demonstrated that EGF stimulates Na+/H+-exchanger 
(NHE) in MDCK cells; NHE is a major pathway of apical 
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Na+ influx in the proximal tubule. Interestingly, this effect
of EGF is reproduced by aldosterone, which transactivates 
the EGF receptor in these cells (109, 110). Although MDCK 
cells are a model of collecting duct principal cells, aldosterone 
increases NHE-3 expression and activity in EGFR-dependent 
manner also in primary culture of human proximal tubule cells 
(111).
 Sodium reabsorption by tubular cells is a two-step process. 
First, Na+ passively enters the cell through the apical mem-
brane, and then in actively extruded across the basolateral 
membrane by Na+,K+-ATPase. Although apical Na+ carriers are 
different in various tubular segment, Na+,K+-ATPase is a com-
mon transporting mechanism along the nephron. In addition, 
Na+,K+-ATPase maintains low intracellular Na+ concentration 
allowing its passive transport from the tubular fluid across the
apical membrane. Thus, Na+,K+-ATPase plays a pivotal role 
in active Na+ reabsorption and is regulated by most, if not all, 
mediators involved in control of Na+ balance (112). Abnormali-
ties of renal Na+,K+-ATPase regulation result in aberrant renal 
Na+ handling and contribute to the development of hyperten-
sion in various experimental models (113). Ten years ago, it 
was demonstrated that EGF increased Na+,K+-ATPase activity 
measured as ouabain-sensitive Rb+ uptake in rat proximal 
tubular cells at rate-limiting Na+ concentration but not under 
Vmax conditions, which suggests that EGF increases enzyme/s 
affinity for sodium but does not change its catalytic rate (114).
Recently, we have demonstrated that EGF infused into the renal 
artery under general anesthesia stimulates, in ERK-dependent 
manner, catalytic activity of renal Na+,K+-ATPase measured 
under Vmax conditions (115). Despite various experimental 
protocols, these two studies (114, 115) suggest that EGF and 
possibly other intrarenally generated EGFR ligands stimulate 
sodium pump in tubular cells.
TRANSACTIVATION OF EGF RECEPTOR IN TUBULAR CELLS 
AND ITS ROLE IN ROS-DEPENDENT ALTERATIONS OF NA+ 
TRANSPORT
Renal Na+ reabsorption is stimulated by mediators which 
reduce natriuresis and increase blood pressure such as nore-
pinephrine and angiotensin II, and inhibited by natriuretic 
factors such as dopamine, nitric oxide and atrial natriuretic 
peptide (112). Little is known about the effect of these media-
tors on EGFR phosphorylation level in tubular cells. However, 
angiotensin II transactivates EGF receptor in rabbit and mouse 
proximal tubular cells (116–118). Moreover, H2O2 transacti-
vates EGFR in opossum kidney cells (119), rabbit proximal 
tubular cells (116) and LLC-PK1 cells (120). In rabbit PCT 
cells, transactivation of EGFR by H2O2 is mediated by c-Src 
and p38 MAPK (121, 122). In rat cultured tubular cell line, 
NRK-52E, endothelin transactivates EGFR by reactive oxygen 
species-dependent mechanism (123). It was demonstrated that 
endothelin stimulates NOX, and NOX-derived ROS transiently 
inactivate Src homology-2 containing protein tyrosine phos-
phatase-1 (SHP-1) thus inhibiting EGFR dephosphorylation 
and increasing its activity. Moreover, α2B adrenergic receptor 
agonists (124), glucose (125), albumin (126) and cyclic stretch 
(127) transactivate EGFR in various tubular segments, partially 
via ROS-dependent mechanism.
 It is possible that a part of antinatriuretic effect of media-
tors such as angiotensin II, norepinephrine and endothelin-1 
is mediated by EGFR. In addition, ROS stimulate tubular Na+ 
transport and therefore, enhanced intrarenal oxidative stress 
may contribute to the development of arterial hypertension 
(128). This antinatriuretic effect of ROS is usually attributed 
to scavenging of nitric oxide, which is generated in the kidney 
in relatively high amounts and exerts a tonic inhibitory effect 
on Na+ transport (129). However, ROS may stimulate Na+ 
reabsorption also in NO-independent manner (130). Indeed, 
hydrogen peroxide stimulates Na+ transport in amphibian A6 
tubular cell monolayers by activating EGFR (131).
 Taking into account these observations, we examined the 
effect of H2O2 infused to the renal artery under general anesthe-
sia on renal Na+,K+-ATPase activity in the rat. We observed 
that H2O2 increased renal cortical and medullary Na+,K+-AT-
Pase activity and this effect was abolished by ERK inhibitor, 
PD98059 (132). Previously, it has been shown that H2O2 
infused into the renal medullary interstitium reduces natriu-
resis and increases blood pressure in the long run (133,134). 
Thus, renal Na+,K+-ATPase may mediate antinatriuretic and 
blood pressure-elevating effect of H2O2. These findings may
explain a “H2O2 paradox”, i.e. the contradictive observations 
that plasma H2O2 level is increased in hypertensive animals 
and humans and that blood pressure is reduced in catalase-
overexpressing mice (which suggests prohypertensive effect 
of H2O2), despite the fact that H2O2 dilates blood vessels and 
may operate as an endothelium-dependent hyperpolarizing 
factor (132). Subsequently, we have demonstrated that H2O2 
increases c-Src phosphorylation level at Tyr418, ERK 1/2 
phosphorylation, and EGFR phosphorylation at Tyr845 and, 
to a lesser extent, at Tyr1068 in the renal cortex and medulla 
(135,136). The effect of H2O2 on c-Src phosphorylation was 
abolished by Src kinase inhibitor, PP2, but not by AG1478 or 
PD98059, its effect on EGFR phosphorylation was abolished 
by PP2 and AG1478, and effect on ERK phosphorylation 
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and Na+,K+-ATPase activity by both these inhibitors as well 
as by PD98059. These data indicate that H2O2 stimulates 
renal sodium pump by the mechanism involving sequential 
activation of c-Src, EGF receptor and ERK (115). Moreover, 
GM6001, CRM197 and anti-HB-EGF neutralizing antibody 
had no effect on H2O2-induced Src-EGFR-ERK pathway at 
doses at which these inhibitors partially attenuated the effect 
of angiotensin II, suggesting that metalloprotease-dependent 
shedding of HB-EGF precursor plays only minor role in the 
stimulation of renal EGFR by H2O2. These results indicate 
that EGFR and ERK-dependent stimulation of Na+,K+-ATPase 
mediates, at least in part, antinatriuretic and prohypertensive 
effects of intrarenal oxidative stress.
EGFR IN EXPERIMENTAL HYPERTENSION
EGFR signaling is enhanced in various animal models of hy-
pertension. Spontaneously hypertensive rat (SHR) is a model 
of essential hypertension which develops independently of 
salt intake. In contrast, Dahl salt-sensitive rats (DSSR) are a 
model of essential hypertension which develops only if dietary 
sodium intake is high. In 1993, Saltis et al (137) have first
noted augmented growth response to EGF of vascular smooth 
muscle cells isolated from SHR in comparison to control cells 
obtained from normotensive Wistar-Kyoto (WKY) rats. How-
ever, EGF receptor density and mRNAEGFR levels were equal in 
both strains, suggesting a postreceptor enhancement of EGFR 
signaling in SHR. Subsequently, Fujino et al. reported that the 
level of HB-EGF in the left ventricle is transiently enhanced 
in SHR during the development of myocardial hypertrophy. 
In addition, the level of mRNAEGFR is permanently higher in 
SHR than in WKY rats (138). Hao et al (62) observed that ac-
tivity of MMP-7 was enhanced in mesenteric arteries of SHR, 
which was accompanied by accelerated HB-EGF processing. 
Interestingly, this was observed at the onset of hypertension (at 
the age of 5 weeks), suggesting that HB-EGF/EGFR signaling 
contributes to the development of hypertension rather than is 
secondary to blood pressure elevation. Moreover, the effect 
of angiotensin II on EGFR and ERK phosphorylation was 
enhanced in aortic smooth muscle cells isolated from SHR 
(139). Consistently with these observations, EGF constricted 
endothelium-denuded thoracic aorta isolated from SHR but 
not from WKY (140).
 Swaminathan and Sambhi (141) observed a 3-fold higher 
density of EGF receptors in the kidney and 2-fold higher recep-
tor density in aorta of Dahl salt-sensitive rats kept on high salt 
diet in comparison to Dahl salt-resistant animals. Moreover, 
affinity of EGFR to its ligand was greater in aorta (but not in
the kidney) of salt-sensitive rats kept on high-salt diet. EGFR 
mRNA and protein levels are greater in the renal cortex of 
DSSR than in salt-resistant rats even before the development 
of hypertension, suggesting that enhanced EGFR signaling 
is not secondary to blood pressure elevation. Interestingly, 
high-salt diet had no effect on EGF receptor abundance in 
the kidney of normotensive Sprague-Dawley rats, but further 
increased receptor density in the kidney of Dahl salt-sensi-
tive rats (142). Moreover, EGF-stimulated phosphorylation 
of EGFR at multiple sites (Tyr845, Tyr992, Tyr1068) in vascular 
smooth muscle cells is greater in Dahl salt-sensitive rats than 
in either Dahl salt-resistant or Sprague-Dawley rats, which 
is accompanied by prolonged ERK and PKB/Akt activation 
(142). Finally, increased EGF receptor density was observed 
in the kidney and aorta of Lyon hypertensive rats compared 
to Lyon normotensive rats (143).
 Controversies exist as to whether EGFR signaling is altered 
in stroke-prone SHR (SHRSP), a substrain of SHR especially 
prone to develop ischemic cerebral stroke. Kim et al (144) 
observed no difference in EGFR expression and phosphoryla-
tion level in aorta between SHRSP and control WKY rats. In 
addition, EGFR phosphorylation in SHRSP was similar before 
(5 week-old animals) and after (10-20 week-old animals) the 
development of hypertension. In contrast, Dorrance et al (145) 
found increased proEGF and EGFR mRNA levels in aorta and 
cerebral arteries of adult SHRSP. In addition, EGFR mRNA 
(but not mRNAproEGF) level was higher in young prehyperten-
sive animals.
 Controversies also exist about role of EGFR in angiotensin 
II-induced hypertension. Kim et al (50) observed that although 
acute infusion of angiotensin II increased EGFR phosphoryla-
tion level in the rat aorta, AII infusion for 3 days had no effect 
on EGFR phosphorylation but stimulated phosphorylation of 
platelet-derived growth factor receptor. In the other study, 
hypertension induced in the rat by 4-week infusion of AII 
was associated with increased mRNAEGFR and protein level in 
aorta, but phosphorylation of the receptor was not examined 
(146). Lautrette et al (147) studied the role of renal EGFR in 
the development of angiotensin II-induced hypertension and 
renal damage. It was demonstrated that infusion of angiotensin 
II for 2 months increased blood pressure by about 40 mmHg in 
mice, which was associated with higher renal  TGFα protein 
(but not mRNA) level, greater ADAM17/TACE activity, and 
enhanced EGFR phosphorylation (but not absolute EGFR 
level) in the kidney. However, expression of a dominant-nega-
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tive EGFR specifically in the proximal tubule, TGFα gene
knockout, or treatment with ADAM17/TACE inhibitor did 
not reduce BP in this model, although these treatments nor-
malized EGFR phosphorylation and prevented renal damage. 
Although these data suggest that renal EGFR is not involved 
in AII-induced hypertension, it should be noted that neither 
of these approaches completely eliminated EGFR signaling. 
Dominant-negative EGFR was expressed only in the proximal 
tubules, TGFα-/- genotype did not eliminate other EGFR lig-
ands, and TACE inhibitor did not block ligand processing by 
other MMP/ADAMs. Thus, although AII is a well-established 
EGFR transactivator (Table 3), role of EGFR in AII-induced 
hypertension is, paradoxically, controversial.
 Several studies examined the role of EGFR in arterial hy-
pertension induced by deoxycorticosterone acetate (DOCA) 
and high-salt diet. Florian et al (148) observed that EGF and 
TGF-α constricted aortic rings isolated from DOCA-salt rats 
but had no effect in normotensive animals. The similar vaso-
constrictor effect was observed in 1-kidney 1-clip hypertension 
model. Constrictor response to EGF was observed after 14 
days of DOCA-salt treatment when blood pressure is already 
elevated. These findings suggest that EGFR does not drive the
development of hypertension in this model, but may contribute 
to the maintenance of high blood pressure. Increased vaso-
constrictor potency of EGF results most likely from excess of 
mineralocorticoids rather than from blood pressure elevation, 
since DOCA-salt treatment induces a similar phenomenon in 
Wistar-Furth rats in which blood pressure only marginally 
increases. Although EGFR mRNA level is increased in aorta 
of DOCA-salt rats, the level of receptor itself is unchanged, 
suggesting that enhanced constricting effect of EGF is a pos-
treceptor phenomenon (149). Enhanced constrictor response 
to EGF in DOCA-salt rats is mediated by ERK, PI3-K, and 
partially by PKC and Rho-dependent kinase (150).
 Chronic administration of synthetic nitric oxide synthase 
inhibitors such as Nω-nitro-L-arginine (L-NNA) or Nω-nitro-
L-arginine methyl ester (L-NAME) is an established model of 
hypertension. It has been shown that EGF contracts thoracic 
aorta of L-NNA-treated hypertensive rats to the greater extent 
than aorta of control animals (140).
EGFR IN LEPTIN-INDUCED AND OBESITY-ASSOCIATED 
HYPERTENSION
Metabolic syndrome (MS) is a commonly observed cluster of 
related abnormalities which directly or indirectly result from 
central obesity. The most important components of MS are 
insulin resistance, hyperinsulinemia, dyslipidemia (reduced 
HDL and increased triglycerides), elevated blood pressure, and 
impaired glucose tolerance or overt type 2 diabetes. Metabolic 
syndrome is a major cause of arterial hypertension. Indeed, 
it is estimated that in developed countries about 2/3 cases of 
arterial hypertension are directly associated with excess body 
weight (151). 
 Little is known about role of EGFR in arterial hypertension 
associated with the MS. Several studies have demonstrated 
increased EGFR phosphorylation level in mesenteric (152), 
coronary (153) and renal arteries (154) of rats with experi-
mental streptozotocin-induced diabetes. In addition, AG1478 
corrects abnormal vascular reactivity (e.g. reduces enhanced 
reactivity to vasoconstrictors and improves impaired reactivity 
to vasodilators) in diabetic but not in control animals. However, 
streptozotocin-induced diabetes is a model of type 1 diabetes, 
which is not a component of MS and is not associated with 
hypertension until nephropathy develops. Recently, increase in 
absolute and phosphorylated EGFR levels was observed in the 
kidney of Goto-Kakizaki rats, a model of type 2 diabetes and 
hypertension (155). However, this model is characterized by 
lower body weight, hypoinsulinemia and hypotriglyceridemia, 
and thus does not reproduce abnormalities associated with the 
MS. 
 Although the mechanism of MS-related hypertension is 
incompletely understood, recent studies suggest an important 
role of adipose tissue-derived signaling proteins designated 
adipokines (156). In particular, leptin, a product of the ob gene, 
is secreted by adipose tissue and regulates energy balance by 
inhibiting food intake and stimulating energy expenditure. 
Several lines of evidence suggest the role of leptin in obes-
ity-associated hypertension (i) plasma leptin concentration is 
increased in obese subjects reflecting greater amount of adi-
pose tissue and resistance to anorectic effect of this hormone, 
(ii) chronic leptin administration or transgenic overexpression 
increase BP in experimental animals, and (iii) high leptin cor-
relates with increased BP in humans independently of body 
weight (157–159). Previously, we and others have examined 
the model of hypertension induced in healthy rats by central 
or peripheral administration of exogenous leptin. Although 
this model does not reproduce all abnormalities associated 
with obesity, it allows studying specific consequences of leptin
excess (158,160). Although the role of EGFR in this model, as 
well as in other models of obesity-associated hypertension, was 
not previously investigated, some observations suggest that 
leptin may be associated with EGFR signaling. First, it was 
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observed 20 years ago that EGFR expression in the liver was 
reduced in three models of obesity associated with deficient
leptin signaling, leptin-deficient ob/ob mice, leptin resistant 
db/db mice, and leptin resistant Zucker fa/fa rat (161). Second, 
EGF and other EGFR ligands such as HB-EGF are produced 
in adipocytes and stimulate adipogenesis, which suggests that 
their production may be enhanced in obesity (162). Indeed, 
plasma HB-EGF positively correlates with body mass index 
(163). Third, unsaturated fatty acids, which circulate in in-
creased amounts in obese subjects, activate EGFR through 
the unknown mechanism (164). Finally, leptin has been shown 
to transactivate the EGF receptor in several cancer cell lines 
(165,166). Nevertheless, until recently, no study examined the 
effect of leptin on EGF receptor in nontransformed cells.
Previously, we have demonstrated that leptin infused into 
the renal artery stimulates renal Na+,K+-ATPase in H2O2 and 
ERK-dependent manner (132). The observation that leptin 
activates ERK in H2O2-dependent manner also in other cell 
types including endothelial cells (167) led us to hypothesize 
that EGFR may be involved in renal effect of leptin. Indeed, 
we demonstrated that stimulation of renal ERK and Na+,K+-
ATPase by leptin is abolished by EGFR inhibitors, AG1478 
and PD158780, as well as by Src inhibitor, PP2. Moreover, the 
effect of leptin was unaffected by GM6001. Taken together, 
these data suggest that leptin stimulates renal sodium pump by 
transactivating the EGF receptor in H2O2 and c-Src dependent 
but MMP-independent manner (115). 
 Likewise, we have recently demonstrated that experimental 
hyperleptinemia induced in normal rats by 7-day administra-
tion of exogenous hormone induces blood pressure elevation 
and impairs Na+ excretion by stimulating renal Na+,K+-ATPase 
(160,168). Moreover, these effects were prevented by NOX 
inhibitor, apocynin, suggesting the involvement of oxidative 
stress (169,170). Therefore, in subsequent studies we aimed 
to elucidate if EGFR-ERK pathway is activated when leptin 
is administered systemically for prolonged period of time and, 
if so, whether this pathway contributes to BP elevation in our 
hyperleptinemic model.
 We demonstrated that leptin infused into the abdominal 
aorta increases EGFR phosphorylation level at Tyr845 and, 
to a lesser extent, Tyr1068, not only in the kidney but also in 
the aortic wall (135). Moreover, leptin stimulated c-Src and 
ERK1/2 phosphorylation in the aortic wall. Although aorta is 
a large conduit artery and does not contribute to the regulation 
of vascular tone, these data suggest that leptin transactivates 
EGFR also in the vascular wall. In addition, we observed that 
if leptin is administered systemically at a dose of 0.5 mg/kg/
day which raises its plasma concentration about fourfold, 
ERKs are transiently stimulated, i.e. ERK1/2 phosphorylation 
level in the kidney and aortic wall is markedly elevated after 
4 days but only moderately elevated after 8 days of leptin 
administration (136). Moreover, ERK inhibitor, PD98059, 
reduced BP in the early phase (3-5 days) but not in the later 
phase (6-8 days) of leptin administration (136). Indeed, later 
phase of leptin-induced hypertension is mainly mediated by 
O2- dependent scavenging of NO (171). Finally, we demon-
strated that systemically administered leptin increases EGFR 
phosphorylation at Tyr845 and Tyr1068 in the aortic wall and 
the kidney, and that administration of AG1478 as well as PP2 
reduces BP in leptin-treated but not in control rats (135). In 
contrast, MMP/ADAM inhibitors, GM6001 or doxycycline, 
had no effect on BP in leptin-treated rats. Recently, Chao et 
al (172) have reported that leptin transactivates EGFR in rat 
vascular smooth muscle cells, which is consistent with our 
previous findings made in intact aortic and renal tissue (115).
Taken together, these data indicate that transactivation of 
EGFR and subsequent stimulation of ERK contribute to the 
development of leptin-induced hypertension by stimulating 
renal Na+,K+-ATPase and, possibly, by inducing vasoconstric-
tion. However, if this mechanism operates in hyperleptinemic 
obese animals and humans, remains to be established.
EGFR AS A TARGET FOR ANTIHYPERTENSIVE THERAPY
Drugs targeting ErbB receptors currently available in clinical 
practice are classified into two groups: (i) antibodies specific
for extracellular receptor domain, and (ii) receptor tyrosine 
kinase inhibitors. Recombinant humanized antibody rec-
ognizing the extracellular domain of ErbB2 (trastuzumab, 
Herceptin) is approved for the treatment of metastatic breast 
cancer. Antibodies specific for EGFR, cetuximab (Erbitux) and
panitumumab (Vectibix), are used in patients with advanced 
metastatic colorectal cancer. Receptor tyrosine kinase inhibi-
tors are categorized as reversible or irreversible. Reversible 
inhibitors compete with the ATP-binding site within the ki-
nase domain, whereas irreversible inhibitors alkylate Cys773 
within the ATP binding pocket and permanently inactivate 
the kinase. Unlike antibodies, most kinase inhibitors have 
broad specificity toward various ErbB receptors. Currently
available reversible inhibitors are quinazoline derivatives. 
Gefitinib (Iressa) and erlotinib (Tarceva) are orally available
derivatives of AG1478 selective for EGFR tyrosine kinase, 
whereas lapatinib targets both EGFR and ErbB2 with com-
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parable activity. Irreversible inhibitors inactivate all members 
of the ErbB family and are effective toward some tumor cells 
resistant to reversible inhibitors. Currently, no irreversible 
inhibitor is approved for therapy but two compounds from 
this group, HKI-272 and BIBW, are in phase II clinical trials 
for the treatment of advanced breast cancer and other solid 
tumors (10). Until now, very little is known about effect of 
these drugs on blood pressure in humans.
 Studies in which attempts have been undertaken to inhibit 
EGFR in experimental hypertension are listed in Table 4. 
These attempts may be divided into two groups. The first group
includes “specific” therapies such as EGFR kinase inhibitors,
as well as inhibitors of transactivation pathways (e.g. Src or 
MMP/ADAM inhibitors). As can be seen, the effect of these 
treatments on BP is controversial. EGFR-specific antisense
oligodeoxynucleotides were used in two studies but only par-
tially reduced blood pressure (173,174). However, antisense 
oligonucleotides only partially reduced total EGFR expression, 
and thus could not completely block its activity. EGFR kinase 
inhibitors were tested in two studies; AG1478 normalized 
blood pressure in leptin-induced hypertension (136), whereas 
gefitinib had no effect on BP in L-NAME induced hyperten-
sion (175). It should be noted that blood pressure is much 
higher in the L-NAME model (mean BP about 170 mmHg) 
than in our study (SBP about 150 mmHg), and L-NAME was 
administered for 4 weeks (175) vs. 1-week leptin treatment 
in our study. It is possible that EGFR blockade is more effec-
tive in reducing BP in moderate than in severe hypertension. 
Among MMP/ADAM inhibitors, doxycycline reduced BP 
in SHR (62), but two more selective inhibitors had no effect 
on BP in angiotensin II-induced or phenylephrine-induced 
hypertension (31,147). It should be noted that doxycycline is 
a broad-range MMP/ADAM inhibitor, whereas compounds 
used in the remaining studies were selective toward specific
ADAMs and therefore could be less effective. 
 Despite these inconsistencies, EGFR is potentially a very at-
tractive target for antihypertensive therapy. First, EGFR is a “fi-
nal common pathway” for various vasoconstrictors and thus its 
inhibition may be more effective than specific therapies aimed
to block only one of these mediators. Second, inhibiting EGFR 
may reduce target organ damage such as glomerulopathy or 
left ventricular hypertrophy even independently of lowering 
BP. Third, some vessel-dilating hypotensive drugs such as Ca2+ 
antagonists or α1-adrenergic receptor antagonists may impair 
renal perfusion and induce fluid retention. If EGFR mediates
enhanced tubular Na+ reabsorption as suggested by some 
studies, inhibiting it may simultaneously normalize vascular 
tone and renal Na+ handling. Finally, hyperleptinemia, which 
accompanies the MS, may contribute to the development of 
malignancies (176,177), possibly via transactivating the EGFR 
(165,166); thus, inhibiting EGFR could simultaneously reduce 
the risk of cancer in hyperleptinemic states.
 EGFR signaling is also affected by less specific antihy-
pertensive therapies such as RAAS inhibitors, ET-1 receptor 
antagonists and antioxidants (Table 4), some of them are well 
established antihypertensive drugs or are known to reduce 
blood pressure in experimental models. The effect of these 
treatments on EGFR was, however, addressed only in few 
studies. Angiotensin-converting enzyme inhibitor, imidapril, 
AT1 receptor antagonist, losartan, and aldosterone antagonist, 
spironolactone, have been shown to reduce EGFR phosphor-
ylation level in some, but not all, studies (Table 4). However, 
each of these drugs has EGFR-independent effects, so the 
causal relationship between inhibiting EGFR and lowering BP 
remains unclear. ERK inhibitor, PD98059, has been consistent-
ly demonstrated to reduce BP in several models of hypertension 
(136,179,180), but ERKs are activated by factors other than 
EGFR, so ERK inhibitors may be more effective than EGFR 
inhibitors. Finally, NOX inhibitor, apocynin, reduces blood 
pressure in many experimental models, but its effect on EGFR 
phosphorylation in vivo is controversial (136,178). In theory, 
other strategies may also be undertaken to inhibit EGFR in hy-
pertension, such as cholesterol depletion in caveolae by drugs 
like statins, AT1 receptor antagonists blocking selectively its 
G-protein independent interaction with EGFR, farnesyltrans-
ferase inhibitors which inhibit farnesylation of Ras proteins, 
or c-Abl inhibitors such as imatinib (Glyvec) currently used 
in the treatment of chronic myelogenous leukemia.
CONCLUSION AND PERSPECTIVES
Data presented above strongly suggest that EGFR is involved 
in the pathogenesis of arterial hypertension, at least in some 
animal models. EGFR is abundantly expressed in the vascular 
wall and renal tubules, and this receptor – either activated by 
its peptide ligand(s) or transactivated by factors such as ROS, 
angiotensin II or leptin – may elicit vasoconstriction and renal 
Na+ retention. Enhanced EGFR signaling has been observed in 
many animal models of hypertension, and inactivation of this 
receptor by genetic or pharmacological approaches reduces 
blood pressure in some of these models.
 Nevertheless, many aspects remain to be clarified. It is
unknown if EGFR plays any role in human hypertension. It 
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Table 4. Targeting EGFR in experimental hypertension
Experimental model Species Treatment Effect oftreatment on BP Other outcomes Ref.
Specific therapies
Angiotensin II infusion 
for 14 days rat
EGFR-AS  
(2 mg/kg total dose) in 
continuous i.v. infusion




(1.5 mg/kg once a 
week for 2 months)
**  total and phosphorylated EGFR in the left ventricle
(174)
L-NAME induced rat gefitinib No change








 EGFR phosphorylation in aorta 
and kidney
(136)
Angiotensin II infusion 




No change Amelioration of renal lesions and EGFR phosphorylation in the kidney (147)
Phenylephrine or 
Angiotensin II infusion 
for 7 days
mice KB-R7785 (ADAM12 inhibitor) No change
Amelioration of left ventricular 
hypertrophy (31)
SHR rat Doxycycline (MMP inhibitor) for 5 weeks 
 HB-EGF shedding in mesenteric 
artery
(62)
Currently used hypotensive drugs
3/4 nephrectomy mice Losartan (AT1 antagonist)

Reduction of renal EGFR 
phosphorylation, TACE activity and 
TGFα level
(147)
Aldosterone + 1% NaCl 
in drinking water rat
Imidapril 
(ACE inhibitor) No change
 EGFR phosphorylation in the left 
ventricle
(178)
SHR rat enalapril +atenolol 
 HB-EGF in the left ventricle, no 
effect on total EGFR***
(138)
Aldosterone + 1% NaCl 
in drinking water rat spironolactone No change
 EGFR phosphorylation in the left 
ventricle
(178)
SHRSP rat spironolactone   EGFR mRNA in aorta (145)





 EGFR phosphorylation in the 
kidney
(155)
Aldosterone + 1% NaCl 
in drinking water rat
apocynin 
(NOX inhibitor) No change
No change in EGFR phosphorylation 





 EGFR phosphorylation in aorta 
and kidney
(136)
AII-induced rat PD98059   ERK phosphorylation in vasculature
(179)
DOCA-salt induced rat PD98059   ERK phosphorylation in vasculature
(180)
Leptin-induced 
hypertension rat PD98059 
 EGFR phosphorylation in aorta 
and kidney
(136)
*moderate decrease in comparison to AII-treated group, but not complete normalization
** reduction of SBP by 10% only in young but not in adult animals.
***no change in absolute level of EGFR mRNA was observed; EGFR phosphorylation was not studied
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is also unclear if other ErbB receptors are transactivated by 
mechanisms similar to EGFR and, if so, whether these recep-
tors are involved in the regulation of vascular tone and renal 
Na+ transport. Currently, it is much too early to recommend 
EGFR inhibitors for the treatment of hypertension. The ef-
fect of these drugs on BP in humans must first be examined,
possibly initially in a subset of patients with hypertension 
and cancers for which these drugs are currently indicated. 
However, even if positive response is observed, the concern 
of possible side effects will remain, especially if it is realized 
that EGFR kinase inhibitors may also target other ErbB recep-
tors, particularly in vivo when compound concentration in all 
compartments cannot be strictly controlled. In this context, it 
should be noted that trastuzumab induces cardiomyopathy in 
a subset of patients (181).
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